article/pii/S0140673624014983 [Additional references continue covering all cited sources from the searches conducted] [1] Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial ScienceDirect science/article/pii/S0140673624014983 [2] The SELECT trial of semaglutide in patients with overweight or obesity without diabetes: establishing a new pathway to secondary prevention of cardiovascular disease PubMed pubmed.ncbi.nlm.nih.gov [3] Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial PubMed pubmed.ncbi.nlm.nih.gov [4] Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial PubMed pubmed.ncbi.nlm.nih.gov [5] GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)
Switch to the simplest recipe (Recipe 9) until tolerance improves
some may see results sooner than others
Xiang H, Wei W, Tan H: Food-grade expression of human glutathione s-transferase and Cu/Zn superoxide dismutase in Lactococcus lactis
Ipamorelin is studied for its selective binding to ghrelin receptors, promoting growth hormone secretion without significant effect on other hormones like cortisol or prolactin
"As one of the fastestgrowing health influences weve seen, GLP1 adoption is reinforcing consumer demand for nutrientdense foods
